K
Kinoxis Therapeutics
Biotech & Life Sciences · Melbourne, Australia · Founded 2017
A biotechnology startup developing new therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric… MoreLess
Kinoxis Therapeutics is a pioneering biopharmaceutical company based in Melbourne, Australia, specializing in the development of therapeutic compounds aimed at enhancing social functioning by targeting specific pathways in the brain. The company primarily focuses on the oxytocin receptor, utilizing selective partial agonism and positive allosteric modulation to restore normal social behavior. Kinoxis serves patients suffering from social dysfunction and substance abuse disorders, operating within the behavioral neuroscience and psychiatric treatment markets. The business model revolves around extensive research and development, backed by significant funding from venture funds like Uniseed and grants from institutions such as the US National Institutes of Health National Institute on Drug Abuse. Revenue is generated through partnerships, licensing agreements, and the commercialization of its therapeutic compounds.
Keywords: biopharmaceutical, oxytocin receptor, social dysfunction, substance abuse, psychiatric treatment, behavioral neuroscience, therapeutic compounds, venture funding, medicinal chemistry, brain pathways.
Company overview
Kinoxis Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Melbourne, Australia
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 74.8
Valuation & funding
Kinoxis Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Dec 2024 | $1.6M | — | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Aug 2024 | $9.4M | $38M | Lis Boyce · Stoic Venture Capital · Avicella Capital · University of Sydney | ↗ |
| EARLY VC✓Equity / VC | May 2022 | $44K | $16M | Brisbane Angels | — |
| GRANT✓Other financing | May 2021 | $32K | — | Innovation Connections | — |
| GRANT✓Other financing | Mar 2021 | $32K | — | Innovation Connections | — |
| SERIES A✓Equity / VC | Dec 2020 | Undisclosed | ↗ | ||
| EARLY VC✓Equity / VC | Dec 2020 | Brisbane Angels | — | ||
| GRANT✓Other financing | Dec 2020 | National Institutes of Health | — | ||
| GRANT✓Other financing | Sep 2019 | National Institutes of Health | — | ||
| SEEDEquity / VC | Sep 2018 | Uniseed Ventures · Stoic Venture Capital | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 18 |
| 2025 | 17 |
| 2024 | 16 |
| 2023 | 14 |
| 2022 | 12 |
| 2021 | 9 |
| 2020 | 7 |
Growth signals
Kinoxis Therapeutics website traffic
Latest recorded traffic for Kinoxis Therapeutics is 1.3K monthly website visits, up 160% over the last three months. Kinoxis Therapeutics's team grew 5.9% over the past year.
Comparisons
Kinoxis Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Kinoxis Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Kinoxis Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Kinoxis Therapeutics has talent and traffic
team presence
In the news
Latest news about Kinoxis Therapeutics
Recent press, funding announcements, and product moves mentioning Kinoxis Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Kinoxis Therapeutics
An AI-synthesized read of the highest-engagement posts about Kinoxis Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kinoxis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.